At-home autologous stem cell transplantation in multiple myeloma with and without G-CSF administration: a comparative study

[1] Morabito F(2002)Feasibility of a mixed inpatient-outpatient model of peripheral blood stem cell transplantation for multiple myeloma Haematologica 87 1192-1199

[2] Martino M(2006)Case-control comparison of at-home to total hospital care for autologous stem-cell transplantation for hematologic malignancies J Clin Oncol 24 4855-4861

[3] Stelitano C(2013)Safety and cost-effectiveness of outpatient autologous stem cell transplantation in patients with multiple myeloma Biol Blood Marrow Transplant 19 547-551

[4] Oliva E(1994)Randomized study of growth factors post-peripheral-blood stem-cell transplant: neutrophil recovery is improved with modest clinical benefit J Clin Oncol 12 661-670

[5] Kropp M(2009)Optimal use of G-CSF administration after hematopoietic SCT Bone Marrow Transplant 43 895-908

[6] Irrera G(2014)Efficacy of deferred dosing of granulocyte colony-stimulating factor in autologous hematopoietic transplantation for multiple myeloma Bone Marrow Transplant 49 219-22

[7] Fernández-Avilés F(2011)SCT without growth factor in multiple myeloma: engraftment kinetics, bacteremia and hospitalization Bone Marrow Transplant 46 956-961

[8] Carreras E(2003)Engraftment syndrome following autologous hematopoietic stem cell transplantation: definition of diagnostic criteria Bone Marrow Transplant 31 393-397

[9] Urbano-Ispizua A(2003)Engraftment syndrome after autologous hematopoietic stem cell transplant supported by granulocyte-colony-stimulating factor (G-CSF) vs granulocyte-macrophage colony-stimulating factor (GM-CSF) Bone Marrow Transplant 31 113-116

[10] Rovira M(2010)Engraftment syndrome after auto-SCT: analysis of diagnostic criteria and risk factors in a large series from a single center Bone Marrow Transplant 45 1417-1422

[1] Morabito F(2002)Feasibility of a mixed inpatient-outpatient model of peripheral blood stem cell transplantation for multiple myeloma Haematologica 87 1192-1199

[2] Martino M(2006)Case-control comparison of at-home to total hospital care for autologous stem-cell transplantation for hematologic malignancies J Clin Oncol 24 4855-4861

[3] Stelitano C(2013)Safety and cost-effectiveness of outpatient autologous stem cell transplantation in patients with multiple myeloma Biol Blood Marrow Transplant 19 547-551

[4] Oliva E(1994)Randomized study of growth factors post-peripheral-blood stem-cell transplant: neutrophil recovery is improved with modest clinical benefit J Clin Oncol 12 661-670

[5] Kropp M(2009)Optimal use of G-CSF administration after hematopoietic SCT Bone Marrow Transplant 43 895-908

[6] Irrera G(2014)Efficacy of deferred dosing of granulocyte colony-stimulating factor in autologous hematopoietic transplantation for multiple myeloma Bone Marrow Transplant 49 219-22

[7] Fernández-Avilés F(2011)SCT without growth factor in multiple myeloma: engraftment kinetics, bacteremia and hospitalization Bone Marrow Transplant 46 956-961

[8] Carreras E(2003)Engraftment syndrome following autologous hematopoietic stem cell transplantation: definition of diagnostic criteria Bone Marrow Transplant 31 393-397

[9] Urbano-Ispizua A(2003)Engraftment syndrome after autologous hematopoietic stem cell transplant supported by granulocyte-colony-stimulating factor (G-CSF) vs granulocyte-macrophage colony-stimulating factor (GM-CSF) Bone Marrow Transplant 31 113-116

[10] Rovira M(2010)Engraftment syndrome after auto-SCT: analysis of diagnostic criteria and risk factors in a large series from a single center Bone Marrow Transplant 45 1417-1422